ColcherD., Horan HandP., NutiM., SchlomJ.A spectrum of monoclonal antibodies reactive with human mammary tumor cells.Proc Natl Acad Sci USA1981; 78: 3119–203.
2.
ThorA., OhuchiN., SzpakC.A., JohnstonW.W., SchlomJ.Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3.Cancer Res1986; 46: 3118–24.
3.
OhuchiN., TakahashiK., MatobaN.Comparison of serum assays for TAG-72, CA19–9 and CEA in gastrointestinal carcinoma patients.Jpn J Clin Oncol1989; 19: 242–8.
4.
ByrneD.J., BrowningM.C.K., CuschieriA.CA 72.4, a new tumour marker for gastric cancer.Br J Surg1990; 77: 1010–3.
5.
GuadagniF., RoselliA., AmatoT.CA 72–4 measurement of tumor-associated glycoprotein 72 (TAG-72) as a serum marker in the management of gastric carcinoma.Cancer Res1992; 52: 1222–7.
6.
FilellaX., FusterJ., MolinaR.TAG-72, CA 19.9 and CEA as tumor markers in gastric cancer.Acta Oncol1994; 33: 747–51.
7.
SafiF., KuhnsV., BergerH.G.Comparison of CA 72–4, CA 19–9 and CEA in the diagnosis and monitoring of gastric cancer.Int J Biol Markers1995; 10: 100–6.
8.
IkeguchiM., KatanoK., SaitouH., TsujitaniS., MaetaM., KaibaraN.Pre-operative serum levels of CA 72–4 in patients with gastric adenocarcinoma.Hepatogastroenterology1997; 17: 2903–6.
9.
MarrelliD., RovielloF., De StefanoA.Prognostic significance of CEA, CA 19–9 and CA 72–4 preoperative serum levels in gastric carcinoma.Oncology1999; 57: 55–62.
10.
GonzálezA., VizosoF., AllendeM.T., SánchezM.T., BalibreaJ.L., RuibalA.Preoperative CEA and TAG-72 serum levels as prognostic indicators in resectable gastric carcinoma.Int J Biol Markers1996; 11: 165–71.
11.
GonzálezA., AllendeM.T., VizosoF., RuibalA.Comportamiento de la glucoproteína asociada a tumores (TAG-72), definida por el monoclonal B72.3 en el suero de pacientes con patologías no tumorales.Rev Clin Esp1990; 186: 362–3.
